Literature DB >> 32043441

Fever Management in Sickle Cell Disease in Low- and Middle-Income Countries: A Survey of SCD Management Programs.

Alexandra L Coria1, Catherine M Taylor2, Venée N Tubman3,4.   

Abstract

Management of fever is a key element of care for children with sickle cell disease (SCD). There exist few studies of current practices in managing fevers in SCD in low- and middle-income countries (LMICs) and malaria-endemic regions where SCD is prevalent. We surveyed medical providers in these settings to characterize current practices in infection prevention and fever management for children with SCD. We found wide variation in use of newborn screening for early diagnosis and infection prevention, pneumococcal vaccination, use of antibiotics and antimalarials, and route of antibiotic administration. Counter to established guidelines, 78% (95% CI: 59-100%) of respondents would consider using oral antibiotics for a febrile child with SCD. Only 17% (95% CI: 0-37%) would administer antibiotics to a well-appearing child with a positive malaria test. Availability of blood cultures did not affect duration of antibiotic course. Further study and standardization of fever management in SCD in LMICs are urgently needed.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32043441      PMCID: PMC7124896          DOI: 10.4269/ajtmh.19-0541

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  18 in total

1.  Newborn screening for sickle cell disease in the Republic of Benin.

Authors:  M C Rahimy; A Gangbo; G Ahouignan; E Alihonou
Journal:  J Clin Pathol       Date:  2009-01       Impact factor: 3.411

Review 2.  Neonatal screening and clinical care programmes for sickle cell disorders in sub-Saharan Africa: lessons from pilot studies.

Authors:  L Tshilolo; E Kafando; M Sawadogo; F Cotton; F Vertongen; A Ferster; B Gulbis
Journal:  Public Health       Date:  2008-06-16       Impact factor: 2.427

Review 3.  Bacterial infection and sickle cell anemia. An analysis of 250 infections in 166 patients and a review of the literature.

Authors:  E Barrett-Connor
Journal:  Medicine (Baltimore)       Date:  1971-03       Impact factor: 1.889

Review 4.  Sickle-cell disease.

Authors:  David C Rees; Thomas N Williams; Mark T Gladwin
Journal:  Lancet       Date:  2010-12-03       Impact factor: 79.321

5.  Pattern of bacteraemia in febrile children with sickle cell anaemia.

Authors:  H O Okuonghae; M U Nwankwo; E C Offor
Journal:  Ann Trop Paediatr       Date:  1993

6.  Malaria in patients with sickle cell anemia: burden, risk factors, and outcome at the outpatient clinic and during hospitalization.

Authors:  Julie Makani; Albert N Komba; Sharon E Cox; Julie Oruo; Khadija Mwamtemi; Jesse Kitundu; Pius Magesa; Stella Rwezaula; Elineema Meda; Josephine Mgaya; Kisali Pallangyo; Emelda Okiro; David Muturi; Charles R Newton; Gregory Fegan; Kevin Marsh; Thomas N Williams
Journal:  Blood       Date:  2009-11-09       Impact factor: 22.113

7.  Bacteraemia in homozygous sickle cell disease in Africa: is pneumococcal prophylaxis justified?

Authors:  M E Kizito; E Mworozi; C Ndugwa; G R Serjeant
Journal:  Arch Dis Child       Date:  2006-03-10       Impact factor: 3.791

Review 8.  Sickle cell disease: new opportunities and challenges in Africa.

Authors:  J Makani; S F Ofori-Acquah; O Nnodu; A Wonkam; K Ohene-Frempong
Journal:  ScientificWorldJournal       Date:  2013-09-19

9.  Bacteraemia in Kenyan children with sickle-cell anaemia: a retrospective cohort and case-control study.

Authors:  Thomas N Williams; Sophie Uyoga; Alex Macharia; Carolyne Ndila; Charlotte F McAuley; Daniel H Opi; Salim Mwarumba; Julie Makani; Albert Komba; Moses N Ndiritu; Shahnaaz K Sharif; Kevin Marsh; James A Berkley; J Anthony G Scott
Journal:  Lancet       Date:  2009-09-09       Impact factor: 79.321

10.  Global burden of sickle cell anaemia in children under five, 2010-2050: modelling based on demographics, excess mortality, and interventions.

Authors:  Frédéric B Piel; Simon I Hay; Sunetra Gupta; David J Weatherall; Thomas N Williams
Journal:  PLoS Med       Date:  2013-07-16       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.